Skip to main content

HSIL, High Grade Squamous Intraepithelial Lesion

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ExeGi Pharma
ExeGi PharmaMD - Rockville
1 program
1
EXE-346 ProbioticPhase 21 trial
Active Trials
NCT06949800Not Yet Recruiting90Est. May 2027

Trial Timeline

Clinical trial activity over time

2026
2027
ExeGi PharmaEXE-346 Probiotic

Clinical Trials (1)

Total enrollment: 90 patients across 1 trials

NCT06949800ExeGi PharmaEXE-346 Probiotic

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Start: Jun 2026Est. completion: May 202790 patients
Phase 2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.